Literature DB >> 28973483

Declining Malaria Transmission Differentially Impacts the Maintenance of Humoral Immunity to Plasmodium falciparum in Children.

Cleopatra K Mugyenyi1,2, Salenna R Elliott2, Xi Zen Yap2,3, Gaoqian Feng2, Philippe Boeuf2,3, Gregory Fegan1, Faith F H Osier1,2,4, Freya J I Fowkes2,5,6, Marion Avril7, Thomas N Williams1,8, Kevin Marsh1, James G Beeson2,3,9.   

Abstract

Background: We investigated the poorly understood impact of declining malaria transmission on maintenance of antibodies to Plasmodium falciparum merozoite antigens and infected erythrocytes (IEs), including functional immunity.
Methods: In a 3-year longitudinal cohort of 300 Kenyan children, antibodies to different AMA1 and MSP2 alleles of merozoites, IE surface antigens, and antibody functional activities were quantified.
Results: Over a period in which malaria transmission declined markedly, AMA1 and MSP2 antibodies decreased substantially; estimated half-lives of antibody duration were 0.8 year and 1-3 years, respectively. However, 69%-74% of children maintained their seropositivity to AMA1 alleles and 42%-52% to MSP2 alleles. Levels and prevalence of antimerozoite antibodies were consistently associated with increasing age and concurrent parasitemia. Antibodies promoting opsonic phagocytosis of merozoites declined rapidly (half-life, 0.15 years). In contrast, complement-fixing antibodies to merozoites did not decline and antibodies to IE surface antigens expressing virulent phenotypes were much better maintained (half-life, 4-10 years). Conclusions: A decline in malaria transmission is associated with reduction in naturally acquired immunity. However, loss of immunity is not universal; some key functional responses and antibodies to IEs were better maintained and these may continue to provide some protection. Findings have implications for malaria surveillance and control measures and informing vaccine development.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Africa; antibodies; complement; immunity; phagocytosis

Mesh:

Substances:

Year:  2017        PMID: 28973483      PMCID: PMC5853596          DOI: 10.1093/infdis/jix370

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  48 in total

1.  Duration of humoral immunity to common viral and vaccine antigens.

Authors:  Ian J Amanna; Nichole E Carlson; Mark K Slifka
Journal:  N Engl J Med       Date:  2007-11-08       Impact factor: 91.245

2.  Human immune responses to the Plasmodium falciparum ring-infected erythrocyte surface antigen (Pf155/RESA) after a decrease in malaria transmission in Madagascar.

Authors:  F Migot; C Chougnet; L Raharimalala; P Astagneau; J P Lepers; P Deloron
Journal:  Am J Trop Med Hyg       Date:  1993-03       Impact factor: 2.345

3.  Patterns of protective associations differ for antibodies to P. falciparum-infected erythrocytes and merozoites in immunity against malaria in children.

Authors:  Jo-Anne Chan; Danielle I Stanisic; Michael F Duffy; Leanne J Robinson; Enmoore Lin; James W Kazura; Christopher L King; Peter M Siba; Freya Ji Fowkes; Ivo Mueller; James G Beeson
Journal:  Eur J Immunol       Date:  2017-09-13       Impact factor: 5.532

4.  Acquisition of antibodies against Plasmodium falciparum merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of response.

Authors:  Danielle I Stanisic; Freya J I Fowkes; Melanie Koinari; Sarah Javati; Enmoore Lin; Benson Kiniboro; Jack S Richards; Leanne J Robinson; Louis Schofield; James W Kazura; Christopher L King; Peter Zimmerman; Ingrid Felger; Peter M Siba; Ivo Mueller; James G Beeson
Journal:  Infect Immun       Date:  2014-11-24       Impact factor: 3.441

5.  Malaria in Africa: progress and prospects in the decade since the Abuja Declaration.

Authors:  Robert W Snow; Kevin Marsh
Journal:  Lancet       Date:  2010-04-22       Impact factor: 79.321

6.  Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria.

Authors:  Michelle J Boyle; Linda Reiling; Gaoqian Feng; Christine Langer; Faith H Osier; Harvey Aspeling-Jones; Yik Sheng Cheng; Janine Stubbs; Kevin K A Tetteh; David J Conway; James S McCarthy; Ivo Muller; Kevin Marsh; Robin F Anders; James G Beeson
Journal:  Immunity       Date:  2015-03-17       Impact factor: 31.745

7.  Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria.

Authors:  Faith Ha Osier; Gaoqian Feng; Michelle J Boyle; Christine Langer; Jingling Zhou; Jack S Richards; Fiona J McCallum; Linda Reiling; Anthony Jaworowski; Robin F Anders; Kevin Marsh; James G Beeson
Journal:  BMC Med       Date:  2014-07-01       Impact factor: 8.775

Review 8.  Research priorities for the development and implementation of serological tools for malaria surveillance.

Authors:  Salenna R Elliott; Freya J I Fowkes; Jack S Richards; Linda Reiling; Damien R Drew; James G Beeson
Journal:  F1000Prime Rep       Date:  2014-11-04

9.  New insights into acquisition, boosting, and longevity of immunity to malaria in pregnant women.

Authors:  Freya J I Fowkes; Rose McGready; Nadia J Cross; Mirja Hommel; Julie A Simpson; Salenna R Elliott; Jack S Richards; Kurt Lackovic; Jacher Viladpai-Nguen; David Narum; Takafumi Tsuboi; Robin F Anders; François Nosten; James G Beeson
Journal:  J Infect Dis       Date:  2012-09-10       Impact factor: 5.226

10.  A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria.

Authors:  Linda M Murungi; Gathoni Kamuyu; Brett Lowe; Philip Bejon; Michael Theisen; Samson M Kinyanjui; Kevin Marsh; Faith H A Osier
Journal:  Vaccine       Date:  2013-06-22       Impact factor: 3.641

View more
  17 in total

Review 1.  Imported Malaria in Countries where Malaria Is Not Endemic: a Comparison of Semi-immune and Nonimmune Travelers.

Authors:  Johannes Mischlinger; Caroline Rönnberg; Míriam J Álvarez-Martínez; Silja Bühler; Małgorzata Paul; Patricia Schlagenhauf; Eskild Petersen; Michael Ramharter
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

2.  B cell profiling in malaria reveals expansion and remodelling of CD11c+ B cell subsets.

Authors:  Christopher Sundling; Caroline Rönnberg; Victor Yman; Muhammad Asghar; Peter Jahnmatz; Tadepally Lakshmikanth; Yang Chen; Jaromir Mikes; Mattias N Forsell; Klara Sondén; Adnane Achour; Petter Brodin; Kristina Em Persson; Anna Färnert
Journal:  JCI Insight       Date:  2019-04-02

3.  Induction and Kinetics of Complement-Fixing Antibodies Against Plasmodium vivax Merozoite Surface Protein 3α and Relationship With Immunoglobulin G Subclasses and Immunoglobulin M.

Authors:  Damian A Oyong; Danny W Wilson; Bridget E Barber; Timothy William; Jianlin Jiang; Mary R Galinski; Freya J I Fowkes; Matthew J Grigg; James G Beeson; Nicholas M Anstey; Michelle J Boyle
Journal:  J Infect Dis       Date:  2019-11-06       Impact factor: 5.226

4.  Selection of Antibody Responses Associated With Plasmodium falciparum Infections in the Context of Malaria Elimination.

Authors:  Lotus L van den Hoogen; Gillian Stresman; Jacquelin Présumé; Ithamare Romilus; Gina Mondélus; Tamara Elismé; Alexandre Existe; Karen E S Hamre; Ruth A Ashton; Thomas Druetz; Vena Joseph; James G Beeson; Susheel K Singh; Jacques Boncy; Thomas P Eisele; Michelle A Chang; Jean F Lemoine; Kevin K A Tetteh; Eric Rogier; Chris Drakeley
Journal:  Front Immunol       Date:  2020-05-15       Impact factor: 7.561

5.  Observational study: 27 years of severe malaria surveillance in Kilifi, Kenya.

Authors:  Patricia Njuguna; Kathryn Maitland; Amek Nyaguara; Daniel Mwanga; Polycarp Mogeni; Neema Mturi; Shebe Mohammed; Gabriel Mwambingu; Caroline Ngetsa; Kenedy Awuondo; Brett Lowe; Ifedayo Adetifa; J Anthony G Scott; Thomas N Williams; Sarah Atkinson; Faith Osier; Robert W Snow; Kevin Marsh; Benjamin Tsofa; Norbert Peshu; Mainga Hamaluba; James A Berkley; Charles R J Newton; John Fondo; Anisa Omar; Philip Bejon
Journal:  BMC Med       Date:  2019-07-08       Impact factor: 8.775

6.  IgM in human immunity to Plasmodium falciparum malaria.

Authors:  M J Boyle; J A Chan; I Handayuni; L Reiling; G Feng; A Hilton; L Kurtovic; D Oyong; K A Piera; B E Barber; T William; D P Eisen; G Minigo; C Langer; D R Drew; F de Labastida Rivera; F H Amante; T N Williams; S Kinyanjui; K Marsh; D L Doolan; C Engwerda; F J I Fowkes; M J Grigg; I Mueller; J S McCarthy; N M Anstey; J G Beeson
Journal:  Sci Adv       Date:  2019-09-25       Impact factor: 14.136

7.  The role of complement immune response on artemisinin-based combination therapy in a population from malaria endemic region of Western Kenya.

Authors:  Christine N L Wanjala; Elke Bergmann-Leitner; Hoseah M Akala; Geoffrey Odhiambo; Bernhards R Ogutu; Ben Andagalu; Edwin Kamau; Daniel Ochiel
Journal:  Malar J       Date:  2020-04-29       Impact factor: 2.979

Review 8.  Complement in malaria immunity and vaccines.

Authors:  Liriye Kurtovic; Michelle J Boyle; D Herbert Opi; Alexander T Kennedy; Wai-Hong Tham; Linda Reiling; Jo-Anne Chan; James G Beeson
Journal:  Immunol Rev       Date:  2019-09-26       Impact factor: 12.988

9.  Framework for Characterizing Longitudinal Antibody Response in Children After Plasmodium falciparum Infection.

Authors:  Eric Rogier; Doug Nace; Pedro R Dimbu; Brian Wakeman; Jan Pohl; James G Beeson; Chris Drakeley; Kevin Tetteh; Mateusz Plucinski
Journal:  Front Immunol       Date:  2021-03-02       Impact factor: 7.561

10.  Community-based molecular and serological surveillance of subclinical malaria in Myanmar.

Authors:  Katherine O'Flaherty; Win Han Oo; Sophie G Zaloumis; Julia C Cutts; Kyaw Zayar Aung; Myat Mon Thein; Damien R Drew; Zahra Razook; Alyssa E Barry; Naanki Parischa; Nyi Nyi Zaw; Htin Kyaw Thu; Aung Thi; Wai Yan Min Htay; Aung Paing Soe; Julie A Simpson; James G Beeson; Paul A Agius; Freya J I Fowkes
Journal:  BMC Med       Date:  2021-05-28       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.